Lord Abbett & CO. LLC acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 684,220 shares of the company's stock, valued at approximately $11,523,000. Lord Abbett & CO. LLC owned about 0.33% of Cellebrite DI as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Telemark Asset Management LLC bought a new stake in shares of Cellebrite DI during the third quarter worth $6,736,000. Two Sigma Advisers LP grew its position in Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock worth $22,584,000 after acquiring an additional 120,000 shares during the last quarter. Scalar Gauge Management LLC increased its holdings in Cellebrite DI by 15.2% in the 2nd quarter. Scalar Gauge Management LLC now owns 453,554 shares of the company's stock worth $5,420,000 after purchasing an additional 60,000 shares in the last quarter. Connors Investor Services Inc. bought a new position in Cellebrite DI in the second quarter valued at about $1,803,000. Finally, Principal Financial Group Inc. bought a new position in Cellebrite DI in the third quarter valued at about $23,402,000. 45.88% of the stock is currently owned by institutional investors.
Cellebrite DI Trading Down 0.3 %
CLBT stock traded down $0.06 during midday trading on Tuesday, hitting $20.23. The stock had a trading volume of 1,184,688 shares, compared to its average volume of 1,178,342. The firm has a market cap of $4.17 billion, a P/E ratio of -13.05, a price-to-earnings-growth ratio of 2.71 and a beta of 1.51. The business has a fifty day moving average price of $18.98 and a two-hundred day moving average price of $15.88. Cellebrite DI Ltd. has a 1-year low of $7.91 and a 1-year high of $21.72.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm's revenue was up 27.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.09 EPS. On average, equities analysts anticipate that Cellebrite DI Ltd. will post 0.32 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on CLBT shares. TD Cowen upped their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a research note on Monday, September 23rd. Needham & Company LLC upped their price target on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Craig Hallum lifted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Monday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI currently has a consensus rating of "Buy" and a consensus target price of $20.57.
Check Out Our Latest Research Report on Cellebrite DI
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
